|
1. |
Impact of the Mode of Detection on Outcome in Breast Cancer Patients Treated With Breast-Conserving Therapy |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 22,
Issue 5,
1999,
Page 429-429
Vijay Kini,
Frank Vicini,
Sandra Victor,
Carl Dmuchowski,
Murray Rebner,
Alvaro Martinez,
Preview
|
|
摘要:
The impact of the mode of detection on outcome in patients with early stage breast cancer treated with breast-conserving therapy (BCT) was reviewed. Between January 1980 and December 1987, 400 cases of stage I and II breast cancer were treated with BCT. All patients underwent an excisional biopsy, external beam irradiation (RT) to the whole breast (45–50 Gy), and a boost to 60 Gy to the tumor bed. One hundred twenty-four cases (31%) were mammographically detected, whereas 276 (69%) were clinically detected. Median follow-up was 9.2 years. Patients whose cancers were detected by mammography more frequently had smaller tumors (90% T1 vs. 62%,p< 0.0001), lower overall disease stage (78% stage I vs. 47%,p< 0.0001), were older at diagnosis (78% >50 years vs. 54%,p< 0.001), less frequently received chemotherapy (8% vs. 21%,p= 0.001), and had an improved disease-free survival (DFS) (80% vs. 70%,p= 0.014), overall survival (OS) (82% vs. 70%,p= 0.005), and cause-specific survival (CSS) (88% vs. 77%,p= 0.003) at 10 years. However, controlling for tumor size, nodal status, and age, no statistically significant differences in the 5- and 10-year actuarial rates of local recurrence (LR), DFS, CSS, or OS were seen based on the mode of detection. Initial mode of detection was the strongest predictor of outcome after a LR. The 3-year DFS rate after LR was significantly better in initially mammographically detected versus clinically detected cases (100% vs. 61%,p= 0.011). Patients with mammographically detected breast cancer generally have smaller tumors and lower overall disease stage at presentation. However, the mode of detection does not independently appear to affect the success of BCT in these patients.
ISSN:0277-3732
出版商:OVID
年代:1999
数据来源: OVID
|
2. |
Early Onset of Breast Carcinoma in African American Women With Poor Prognostic Factors |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 22,
Issue 5,
1999,
Page 436-436
Hassan Aziz,
Fazal Hussain,
Chul Sohn,
Rene Mediavillo,
Audrey Saitta,
Aneela Hussain,
Mark Brandys,
Peter Homel,
Marvin Rotman,
Preview
|
|
摘要:
The purpose of this study was to determine prognostic significance of age and race as independent variables and to see role of age at the onset of breast carcinoma. A retrospective study was conducted of African American and white women with breast cancer treated at SUNY–Health Science Center Brooklyn and Kings County Hospital Center from 1983 to 1993. The objective was to analyze the differences in patterns of disease onset, as related to age and prognostic factors. A total of 738 patients were analyzed for race-adjusted comparison of stage, grade, disease-free survival, and median survival. Age at the time of diagnosis was analyzed to conduct age-specific comparisons of African American (AA) and white patients. The multivariate analysis indicated that AA women develop breast cancer 10 years earlier than white women (p= 0.00001). Corrected by stage and grade, i.e., &khgr;2test for stage-by-stage and grade-by-grade analysis has revealed that the AA women present with higher stage (p= 0.009), increased number of positive nodes (p= 0.00007), and more estrogen receptor/progesterone receptor–negative tumors (p= 0.005). Further studies are required to probe into the etiologic possibilities of this significant difference. The important contributing factors could be hormonal, genetic, environmental, and socioeconomic. Obesity and dietary factors also need to be evaluated. Further studies to explore genetic susceptibility by ploidy is recommended to explain this significant difference. We conclude that the onset of breast cancer among AA women occurs at a significantly younger age than in white women, and their prognostic factors are poorer.
ISSN:0277-3732
出版商:OVID
年代:1999
数据来源: OVID
|
3. |
High-Dose Hemithorax Irradiation in a Patient With Recurrent ThymomaA Study of Pulmonary and Cardiac Radiation Tolerance |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 22,
Issue 5,
1999,
Page 441-441
Jeffrey Bogart,
Robert Sagerman,
Preview
|
|
摘要:
Malignancy spread throughout a hemithorax without distant metastasis poses a difficult therapeutic challenge. Irradiation is often not considered because of the risk of pulmonary and cardiac toxicity. We report on a patient with thymoma recurrent throughout the left pleural cavity. Disease progressed despite chemotherapy, and subsequently a radical course of radiotherapy (6,600 cGy) was delivered to the entire hemithorax. Tumor regressed markedly by the completion of radiotherapy. Although tumor regrowth was noted 1 year after radiotherapy, the patient remained markedly improved symptomatically until shortly before her death 2 years after radiotherapy. Pulmonary function tests at 1 year (forced expiratory volume of the first second and forced vital capacity) were similar to pretreatment values, and cardiac function at 2 years remained essentially normal. High-dose hemithorax irradiation may be a consideration in select cases.
ISSN:0277-3732
出版商:OVID
年代:1999
数据来源: OVID
|
4. |
‘Neo-FAC’ (5-Fluorouracil, Doxorubicin, and Cyclophosphamide) for Poor-Prognosis Stage IV Breast CancerA Southwest Oncology Group Phase II Study |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 22,
Issue 5,
1999,
Page 446-446
Georgiana Ellis,
Stephanie Green,
Robert Livingston,
Michael Kraut,
H. Pierce,
Jorge Paradelo,
Sarah Taylor,
Silvana Martino,
Preview
|
|
摘要:
The authors report a phase II pilot investigation in the Southwest Oncology Group examining a combination of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) incorporating modulated 5-FU in patients with poor-prognosis stage IV breast cancer. Patients with poor-prognosis stage IV breast cancer were treated with this “neo-FAC” as front-line therapy. The regimen consisted of 5-fluorouracil by continuous ambulatory infusion pump at 200 mg/m2/day for 42 days, repeated at 56-day intervals; doxorubicin at 20 mg/m2/week intravenously to a maximum cumulative total dose (including adjuvant therapy, if any) of 500 mg/m2; cyclophosphamide 60 mg/m2/day taken orally; methotrexate 15 mg/m2/week intravenously beginning 1 week after termination of doxorubicin; and oral prednisone decreasing from 60 mg/day on a tapering schedule for a total of 7 weeks of treatment. Treatment was continued until progression, unacceptable toxicity, or patient refusal. Twenty-four patients were accrued to this study. Of these, two were ineligible, and the remaining 22 were evaluable for response. Ten patients experienced grade 3 toxicity, and six had grade 4. There were no treatment-associated deaths. Best responses were a complete response in one patient (5%) and partial responses in 6, for an overall response rate of 32% (7/22 evaluable patients). Overall survival in five pilot studies in the Southwest Oncology Group in this poor-prognosis population are relatively superimposable. The present regimen, with its relatively poor outcome and the expense and inconvenience of administering chemotherapy by ambulatory infusion pump, will not be pursued further.
ISSN:0277-3732
出版商:OVID
年代:1999
数据来源: OVID
|
5. |
Gemcitabine Salvage Chemotherapy for Patients With Gynecologic Malignancies of the Ovary, Fallopian Tube, and Peritoneum |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 22,
Issue 5,
1999,
Page 450-450
David Silver,
M. Piver,
Preview
|
|
摘要:
The efficacy and toxicity of gemcitabine salvage chemotherapy was evaluated in 27 heavily pretreated patients with recurrent and progressive ovarian, fallopian tube, or peritoneal cancer. At least one platinum-based chemotherapeutic regimen had failed in each patient. The median number of previous chemotherapy regimens and cycles of chemotherapy was 4 and 23, respectively. A total of 124 cycles of gemcitabine were delivered (median, 3 cycles). Hematologic toxicity included four patients with grade 3/4 thrombocytopenia and two patients with grade 3/4 neutropenia. Thrombocytopenia and neutropenia resulted in eight dose reductions and a single 1-week treatment delay. Nonhematologic side effects were well tolerated and largely self-limiting. No complete responses were observed. Three patients (11%) demonstrated partial responses to therapy. The duration of response was 7 months for two of the responders and 5 months for the third responder. Stable disease was observed in 14 patients (52%), in whom the median progression-free interval was 5 months. In conclusion, among heavily pretreated patients, gemcitabine has limited antitumor activity in platinum-resistant carcinomas of the ovary, fallopian tube, and peritoneum. The role of gemcitabine in the treatment of gynecologic malignancies of the ovary, fallopian tube, and peritoneum will be determined by studies that define the efficacy of multiagent regimens of chemotherapy that include gemcitabine and by studies that include patients who have been less heavily pretreated.
ISSN:0277-3732
出版商:OVID
年代:1999
数据来源: OVID
|
6. |
Clinical Factors and Prognosis in Non–Small Cell Lung Cancer |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 22,
Issue 5,
1999,
Page 453-453
Sandro Martins,
José Pereira,
Preview
|
|
摘要:
We evaluated the relationship of clinical characteristics and survival in 1,635 patients with non–small cell lung cancer (NSCLC) treated in Brazil. The following variables were included: sex, age, smoking, Karnofsky’s performance status (PS), weight loss, symptoms at diagnosis (cough, dyspnea, hemoptysis, chest pain, wheezing, and hoarseness), presence of superior vena cava syndrome (SVCS), histologic type, TNM stage, and therapeutic modality (surgery, chemotherapy [CT] and radiotherapy [RT]). Multivariate prognostic models were obtained by Cox regression. Patients unsuitable for surgery or who had recidivant disease were elected to further RT and/or CT, and long-term results in this group were equivalent to those in the group treated only by surgery. A diagnosis of bronchioloalveolar carcinoma, small tumors, absence of hoarseness, treatment by surgery, and RT were independent factors related to good overall survival in stage I and II. Weight loss and clinical signs of SVCS were related to poor prognosis in stage III. PS, diagnosis of adenocarcinoma or undifferentiated carcinoma, absence of weight loss and dyspnea, N0 or N1 disease, ability to receive RT, CT, and to perform some palliative surgical procedure were good prognostic factors in stage IV. Clinical features of patients with NSCLC at diagnosis offer additional information to estimate their prognosis.
ISSN:0277-3732
出版商:OVID
年代:1999
数据来源: OVID
|
7. |
Primary Appendiceal Adenocarcinoma |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 22,
Issue 5,
1999,
Page 458-458
Ayşegül Özakyol,
Tülay Sariçam,
Sare Kabukçuoğlu,
Tarik Çağa,
Esat Erenoğlu,
Preview
|
|
摘要:
Adenocarcinoma of the appendix is rarely encountered and is usually discovered at the pathology examination of the surgical specimen. Adenocarcinoma of the vermiform appendix is a rare neoplasm and constitutes <0.5% of all gastrointestinal neoplasms. There is no symptom of appendiceal cancer, and it is very difficult to diagnose preoperatively. Most female patients are diagnosed as having a gynecologic disease. Second primary synchronous and metachronous neoplasms, especially in the gastrointestinal tract, are found in up to 35% of patients with appendix adenocarcinoma. We report a case of adenocarcinoma in a 56-year-old woman misdiagnosed as having right ovarian carcinoma, and we review the literature.
ISSN:0277-3732
出版商:OVID
年代:1999
数据来源: OVID
|
8. |
Primary Cardiac Sarcoma in PregnancyA Case Report and Review of the Literature |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 22,
Issue 5,
1999,
Page 460-460
Giovanni Ceresoli,
Paolo Passoni,
Stefano Benussi,
Ottavio Alfieri,
Giacomo Dell’Antonio,
Angelo Bolognesi,
Preview
|
|
摘要:
Primary cardiac sarcoma (PCS) is a rare disease with a poor prognosis, because of diagnostic delay, therapeutic difficulties, and high metastatic potential. Surgery is the standard treatment. A case of PCS in pregnancy is reported, with a review of published surgical series of PCSs, focusing on the role of surgery and adjuvant therapy. Prompt surgery improved cardiac function and patients’ outcome in comparison with untreated cases. The role of adjuvant treatment was analyzed only in a few series, mainly without distinction between postoperative chemotherapy and radiotherapy; adjuvant therapy improved survival in the larger series of resected PCSs. Only three other cases of PCS in pregnancy were reported. In the present case, resection was performed with no major complication for the mother and the infant. Even if the patient’s survival was short, cardiac surgery allowed prolonging of pregnancy until an acceptable possibility of fetal survival was reached. Although resection is not curative in most cases, surgery remains the treatment of choice for PCS and has a definite palliative significance. The role of postoperative chemotherapy and radiotherapy is difficult to ascertain; however, adjuvant chemotherapy seems advisable in high-grade tumors.
ISSN:0277-3732
出版商:OVID
年代:1999
数据来源: OVID
|
9. |
Severe Cardiotoxicity During 5-Fluorouracil ChemotherapyA Case and Literature Report |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 22,
Issue 5,
1999,
Page 466-466
Christiane Kuropkat,
Katherine Griem,
James Clark,
E. Rodriguez,
James Hutchinson,
Samuel Taylor,
Preview
|
|
摘要:
The chemotherapeutic agent 5-fluorouracil (5-FU) is a widely accepted part of many cancer treatment protocols. Its cardiotoxic potential is known, but considered uncommon and usually not life threatening, although some cases of severe cardiotoxicity related to 5-FU have been reported. The pathogenesis of cardiotoxicity caused by 5-FU is not clear. We report a case of sudden onset of severe cardiac failure, without ischemic symptoms or signs, during 5-FU treatment with serious consequences, in a previously healthy 23-year-old patient with squamous cell carcinoma of the tongue. Endomyocardial biopsy showed proliferation of the sarcoplasmic reticulum with marked vacuolization, similar to that found with doxorubicin cardiotoxicity. Because 5-FU cardiotoxicity is unpredictable and can have potentially fatal consequences, it requires, in our opinion, further clarification. With this well-documented case, including an endomyocardial biopsy, we hope to encourage additional efforts to investigate the pathophysiologic mechanisms of 5-FU cardiotoxicity.
ISSN:0277-3732
出版商:OVID
年代:1999
数据来源: OVID
|
10. |
Combination of Epirubicin and Cisplatin in Hormone-Refractory Metastatic Prostate Cancer |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 22,
Issue 5,
1999,
Page 471-471
Susan Huan,
David Stewart,
Susan Aitken,
Roanne Segal,
Jonathan Yau,
Preview
|
|
摘要:
Anthracyclines and cisplatin have been shown separately to have modest activity in prostate cancer. The synergism between anthracyclines and cisplatin, with the lack of overlapping toxicities, led to the conduct of this phase II trial of the combination of epirubicin and cisplatin in hormone-refractory metastatic prostate cancer. Twenty-one evaluable patients with hormone-refractory metastatic prostate cancer received epirubicin 100 mg/m2followed by cisplatin 80 mg/m2with prehydration and mannitol diuresis. Epirubicin and cisplatin produced a biochemical response (>50% decrease in tumor marker) in 32% of patients, symptomatic improvement in 38%, and a response in measurable and evaluable disease sites in 14%. Toxicities were mainly hematologic, with 77% and 41% >grade 2 neutropenia and thrombocytopenia, respectively. Greater than grade 2 toxicities were: cardiac (three), renal secondary to sepsis (one), nausea and vomiting (two), weakness (one), mucositis (one), and diarrhea (one). The combination of epirubicin and cisplatin was associated with manageable toxicities in this elderly population; however, antitumor activity was marginal in this disease. Participation in clinical trials should continue to be offered to patients with hormone-refractory metastatic prostate cancer.
ISSN:0277-3732
出版商:OVID
年代:1999
数据来源: OVID
|
|